HAE Update: Determining optimal patient specific therapy

Allergy and Asthma Proceedings

Volumn 34, Issue 1, 2013, Pages 7-12

  Gower, Richard G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ B2 RECEPTOR; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; PLASMA KALLIKREIN;

ACNE; AMENORRHEA; ANDROGEN THERAPY; ANGIONEUROTIC EDEMA; CONFERENCE PAPER; DIARRHEA; DRUG CONTRAINDICATION; DRUG HALF LIFE; DYSPEPSIA; FATIGUE; HEADACHE; HEMORRHAGIC CYSTITIS; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INDIVIDUALIZATION; INJECTION SITE ERYTHEMA; LIBIDO DISORDER; LIVER TOXICITY; LONG TERM CARE; MEDICAL HISTORY; MYALGIA; NAUSEA; PATIENT PREFERENCE; PRACTICE GUIDELINE; PROPHYLAXIS; QUALITY OF LIFE; SIDE EFFECT; SUBSTITUTION THERAPY; TREATMENT OUTCOME; VIRILIZATION; WEIGHT GAIN;

ANDROGENS; ANGIOEDEMAS, HEREDITARY; BRADYKININ; COMPLEMENT C1 INACTIVATOR PROTEINS; DISEASE PROGRESSION; HUMANS; INDIVIDUALIZED MEDICINE; KALLIKREINS; PEPTIDES; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, BRADYKININ B2; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84874321467     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2013.34.3624     Document Type: Conference Paper

References (32)

1. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 6:24, 2010.
2. Frank MM, Gelfand JA, and Atkinson JP. Hereditary angioedema: The clinical syndrome and its management. Ann Int Med 84:580-593, 1976.
3. Frank MM. Hereditary angioedema: The clinical syndrome and its management in the United States. Immunol Allergy Clin North Am 26:653-668, 2006. (Pubitemid 44666309)
4. Bork K, Hardt J, Schicketanz KH, and Ressel N. Clinical studies of sudden upper airway obstruction in patients with hereditary angioedema due to C1 esterase inhibitor deficiency. Arch Intern Med 163:1229-1235, 2003. (Pubitemid 36613077)
5. Zuraw BL, and Christiansen SC. Pathophysiology of hereditary angioedema. Am J Rhinol Allergy 25:373-378, 2011.
6. Bork K, Siedlecki K, Bosch S, et al. Asphyxiation by laryngeal edema in patients with hereditary angioedema. Mayo Clin Proc 75:349-354, 2000. (Pubitemid 30187107)
7. Lumry WR, Castaldo AJ, Vernon MK, et al. The humanistic burden of hereditary angioedema: Impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 31:407-414, 2010.
8. Bork K, Meng G, Staubach P, et al. Hereditary angioedema: New findings concerning symptoms, affected organs, and course. Am J Med 119:267-274, 2006. (Pubitemid 43255068)
9. Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin Immunol 6:19, 2010.
10. Dagen C, and Craig TJ. Treatment of hereditary angioedema: Items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol 6:11, 2010.
11. Aberer W, Hoffmann T, Wiednig M, et al. A study of the self-administration of icatibant for acute attacks of hereditary angioedema (HAE). Ann Allergy Asthma Immunol 105:A92, 2010.
12. Busse PJ. Angioedema: Differential diagnosis and treatment. Allergy Asthma Proc 32(suppl 1):S3-S11, 2011. (PubMed PMID: 22195755.)
13. Tourangeau LM, and Zuraw BL. The new era of C1-esterase inhibitor deficiency therapy. Curr Allergy Asthma Rep 11:345-351, 2011.
14. MacGinnitie AJ, Campion M, Stolz LE, and Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: Analysis of efficacy by patient characteristics. Allergy Asthma Proc 33:178-185, 2012. (PubMed PMID: 22525395.)
15. Zilberberg MD, Nathanson BH, Jacobsen T, and Tillotson G. Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007. Allergy Asthma Proc 32:248-254, 2011. (Epub May 4, 2011; PubMed PMID: 21549036.)
16. Bernstein JA. Update on angioedema: Evaluation, diagnosis, and treatment. Allergy Asthma Proc 32:408-412, 2011. (PubMed PMID: 22221433.)
17. Grant JA, White MV, Li HH, et al. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks. Allergy Asthma Proc 33:348-353, 2012. (PubMed PMID: 22856635.)
18. Gower RG, Lumry WR, Davis-Lorton MA, et al. Current options for prophylactic treatment of hereditary angioedema in the United States: Patient-based considerations. Allergy Asthma Proc 33:235-240, 2012. (PubMed PMID: 22584192.)
19. Frank MM. Update on preventive therapy (prophylaxis) of hereditary angioedema. Allergy Asthma Proc 32:17-21, 2011. (PubMed PMID: 21262094.)
20. Bork K, Bygum A, and Hardt J. Benefits and risks of danazol in hereditary angioedema: A long-term survey of 118 patients. Ann Allergy Asthma Immunol 100:153-161, 2008. (Pubitemid 351238551)
21. Bork K, Meng G, Staubach P, and Hardt J. Treatment with C1-INHibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 45:1774-1784, 2005. (Pubitemid 43923905)
22. Craig TJ, Levy R, Wasserman R, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801-808, 2009.
23. Craig TJ, Bewtra AK, Hurewitz D, et al. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks. Allergy Asthma Proc 33:354-361, 2012. (PubMed PMID: 22856636.)
24. Bork K, and Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1-INHibitor concentrate in patients with hereditary angioedema. Arch Intern Med 161:714-718, 2001. (Pubitemid 32200225)
25. Zuraw B, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 363:513-522, 2010.
26. Levy RJ, Lumry W, McNeil D, et al. EDEMA4: A phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 104:523-529, 2010.
27. Zuraw BL. Novel therapies for hereditary angioedema. Immunol Allergy Clin North Am 26:691-708, 2006. (Pubitemid 44666311)
28. Lumry WR, Li HH, Levy RJ, et al. Results from FAST-3: A phase III randomized, double-blind, placebo-controlled, multicenter study of subcutaneous icatibant in patients with acute hereditary angioedema (HAE) attacks. J Allergy Clin Immunol 127: AB1, 2011.
29. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 6:22, 2010.
30. Landmesser L, Tillotson G, and Mariano D. Site of care of nanofiltered C1 esterase inhibitor [human](Cinryze) in patients with hereditary angioedema (HAE). Ann Allergy Asthma Immunol 105:A113, 2010.
31. Dispenza MC, and Craig TJ. Discrepancies between guidelines and international practice in treatment of hereditary angioedema. Allergy Asthma Proc 33:241-248, 2012. (PubMed PMID: 22584193.)
32. Cicardi M, Bork K, Caballero T, et al., on behalf of HAWK (Hereditary Angioedema International Working Group). Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 67:147-157, 2012.